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ABSTRACT: The ribosomally synthesized and post-transla-
tionally modified peptide (RiPP) bottromycin A2 possesses 
potent antimicrobial activity. Its biosynthesis involves the en-
zymatic formation of a macroamidine, a process previously 
suggested to require the concerted efforts of a YcaO enzyme 
(PurCD) and an amidohydrolase (PurAH) in vivo. In vitro, 
PurCD alone is sufficient to catalyze formation of the 
macroamidine, but the process is reversible. We set out to 
probe the role of PurAH in macroamidine formation in vitro. 
We demonstrate that PurAH is highly selective for macroam-
idine-containing precursor peptides and cleaves C-terminal of 
a thiazoline, thus removing the follower peptide. After fol-
lower cleavage, macroamidine formation is irreversible, indi-
cating PurAH as the gatekeeper of bottromycin biosynthesis. 
The structure of PurAH suggests residues involved in cataly-
sis, which were probed through mutagenesis. 
Bottromycins1-2 are natural product antibiotics with activity 
against problematic human pathogens such as Methicillin-re-
sistant Staphylococcus aureus (MRSA)3-4. They bind to the A-
site of the prokaryotic 50S ribosome, which is a novel antibiotic 
target5-7. Bottromycins belong to the growing family of riboso-
mally synthesized and post-translationally modified peptides 
(RiPPs), and their biosynthesis and total synthesis have received 
increasing attention8-12. They are derived from the precursor pep-
tide BotA, which undergoes a series of post-translational enzy-
matic tailoring steps, the order of which has been proposed based 
on an untargeted metabolomics approach using mass spectral 
networking (Scheme 1, we will use Streptomyces sp. BC16019 
nomenclature)13: First, the N-terminal methionine is removed 
by a leucyl-amino peptidase (BotP), followed by heterocycliza-
tion of the BotA cysteine residue to thiazoline by the YcaO en-
zyme BotC and Cb-methylation by radical methyl transferases 1-
3. Next, a second YcaO enzyme, BotCD, was reported to act to-
gether with the metallo-dependent amidohydrolase BotAH in 
macroamidine formation13. Removal of the follower peptide by 
the a/b-hydrolase BotH, successive oxidative decarboxylation of 
the thiazoline to a thiazole (BotCYP) and O-methylation of an 
aspartate (BotOMT) complete bottromycin biosynthesis. 
Scheme 1. (a) A gene cluster highly homologous in se-
quence and organization to those of confirmed bottromy-
cin producers Streptomyces sp. BC16019 and S. bottro-
pensis was found in S. purpureus (top). Intergenic regions 
not drawn to scale. (b) Bottromycin biosynthesis as pro-
posed by untargeted metabolomics13. Methylation by rad-
ical methyl transferases (RMT1-3) is shown as black lines, 
heterocyclized cysteine as a red pentagon and the 
macroamidine in cyan. 
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In vitro work has confirmed the assigned functions for BotP13-14, 
BotC8-9 and BotCD8-9. It was demonstrated that the BotCD hom-
ologs BmbE and PurCD alone are sufficient for macroamidine 
formation in vitro8-9. For PurCD, macroamidine formation was 
reversible: It catalyzes both, macroamidine formation and its re-
opening8. 
To probe the role of the amidohydrolase in bottromycin biosyn-
thesis in vitro, we attempted to express BotAH (insoluble). The 
close homolog PurAH (72 % sequence identity to BotAH) from 
Streptomyces purpureus (Scheme 1) could be expressed and pu-
rified. We first tested possible substrates and incubated PurAH 
with precursor peptide BotA, BotAP (N-terminal methionine re-
moved), BotAPC (BotAP with heterocyclized cysteine) and 
BotAPCCD (macrocyclized BotAPC) (Figure 1a). 
 
Figure 1. LC-ESI-MS characterization of PurAH reactions. (a) 
Incubation of PurAH with BotA, BotAP, BotAPC, and BotAPCCD 
(5 µM enzyme, 50 µM substrate, 37 °C, 16 h). Only BotAPC and 
BotAPCCD were substrates of PurAH. Colors correspond to 
scheme 1. (b) Time-course of BotAPC and BotAPCCD (50 µM) 
cleavage by PurAH (0.2 µM) in the presence of Co2+ (100 µM). 
(c) When PurAH is added to a macrocyclization reaction, the re-
action goes to completion and 2 is formed. 
All samples were analyzed by liquid chromatography-elec-
trospray ionization mass spectrometry (LC-ESI-MS). We ob-
served no activity on BotA or BotAP. For the BotAPC reaction, we 
observed two new masses, which corresponded to the heterocy-
clized BotA core peptide (1, Figure S1A) (m/z calcmono.: 
816.3840 Da, observed: 816.3814 Da, error -3.2 ppm) and the 
follower peptide (m/z calcmono.: 3857.62 Da, observed: 3857.63 
Da, error 2.6 ppm), but the reaction was incomplete. For the 
BotAPCCD reaction, the substrate was consumed completely and 
two new masses appeared: One corresponded to the heterocy-
clized, macroamidine-containing BotA core peptide (2, Figure 
S1b), while the other corresponded to the follower peptide (m/z 
calcmono.: 798.3734 Da, observed: 798.3706 Da, error -3.5 ppm 
and m/z calcmono.: 3857.62 Da, observed: 3858.63 Da, error 2.6 
ppm), respectively. The identity of 1 and 2 was confirmed by 
MS2 (Figure S2, Tables S1 and S2). These data demonstrate that 
PurAH is responsible for removing the follower peptide during 
bottromycin biosynthesis. Since the protein is annotated as a 
metal-dependent amidohydrolase, we dialyzed purified PurAH 
extensively with EDTA to remove endogenous metal ions and set 
up reactions of PurAH with BotAPCCD using different divalent 
metal ions (Figure S3). No activity was observed for CdCl2 and 
NiCl2, while addition of FeCl2 or MgCl2 accelerated the back-
ground rate slightly. MnCl2 << ZnCl2 < CoCl2 each led to appre-
ciable turnover, with Co2+ giving best activity. A time course ex-
periment with 0.2 µM PurAH and 50 µM BotAPC or BotAPCCD re-
vealed that the reaction using BotAPCCD was complete after 80 
min, while no product formation was detectable in the same time 
frame using BotAPC (Figure 1b). PurAH is thus highly selective 
for the heterocyclized, macrocyclized intermediate BotAPCCD and 
removes the follower peptide. 
With the function of the amidohydrolase established we investi-
gated its involvement in macroamidine formation. The 
macroamidine forming YcaO enzyme PurCD converts BotAPC 
into BotAPCCD in an ATP/Mg2+-dependent reaction for which the 
BotA follower peptide is essential8-9. We have shown that this re-
action is reversible – purified BotAPCCD incubated with PurCD 
and ATP/MgCl2 will be converted back to BotAPC, now lacking 
the macrocycle (Figure S4)8. Given the very strong preference of 
PurAH for BotAPCCD and the dependence of PurCD activity on 
the presence of the follower peptide that is removed by PurAH, 
we hypothesized that PurAH may prevent re-opening of the mac-
rocycle. First, we purified 2 and incubated it with PurCD and 
ATP/MgCl2. Even after extensive incubation times at 37 °C, we 
did not observe reopening of the macroamidine to yield 1 (Fig-
ure S4). BotAPCCD on the other hand converted readily back to 
BotAPC (Figure S4). When BotAPC is incubated with PurCD un-
der optimized conditions, the turnover to BotAPCCD does not ex-
ceed 70 %.8 However, when PurAH is added to the reaction, we 
observe complete conversion of BotAPC to 2, indicating complete 
conversion of BotAPC (macroamidine formation) and subse-
quent removal of the follower peptide (Figure 1c). These data ra-
tionalize why the amidohydrolase was reported as essential for 
macroamidine formation in vivo13 – knocking out PurAH likely 
leads to reopening of the macroamidine and prevented down-
stream processing. This places PurAH as the gatekeeper of bot-
tromycin biosynthesis, that removes the follower peptide once all 
enzymes requiring the follower have acted on the precursor pep-
tide. 
To understand how PurAH selects for the macrocycle in 
BotAPCCD, we determined the PurAH crystal structure to 1.73 Å 
resolution. All data collection and refinement statistics can be 
found in Table S3. The refined model contained one protomer 
in the asymmetric unit and includes residues 9 – 74 and 78 – 460 
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(Figure S5). Two Zn2+ ions are coordinated at the active site: Zn1 
by His210 and His229, Zn2 by His94, His96 and Asp348. Lys183 
has been carboxylated as commonly observed in amidohydro-
lases15, with each oxygen coordinating one Zn2+ (Figure S5). The 
distorted trigonal bipyramidal coordination of the two Zn2+ is 
completed by ordered water molecules, one of which bridges the 
two Zn2+ ions. This bridging water may be an activated hydroxyl 
known to facilitate catalysis in amidohydrolases16-19. We gener-
ated a sequence similarity network (SSN) for PurAH (Figure 
S6a) and found it to be part of a small node that exclusively con-
tained PurAH homologs from all known bottromycin biosyn-
thetic gene clusters. Mapping the sequences of this node onto the 
PurAH structure using ConSurf20-23, we found residues surround-
ing the active site to be highly conserved (Figure 2a). In contrast, 
the closest structural homologs identified by a DALI24 search 
show virtually no sequence conservation at the active site (Figure 
2b). PurAH contains an extended, wide binding site that may 
have evolved specifically to accept branched cyclic peptide sub-
strates (Figure S6b). 
 
Figure 2. (a) and (b) Consurf maps showing the conservation of 
residues around the PurAH active site (arrow) for (a) PurAH 
homologs from other bottromycin biosynthetic gene clusters 
(PurAH containing node, Figure S6a) and (b) the closest struc-
tural homologs identified by a DALI search (Figure S6b). (c) 
Schematic view of the conversion of 13 BotA mutants designed 
to test PurAH promiscuity.  
To rationalize PurAH’s selectivity, we sought to determine the 
complex crystal structure of PurAH with its substrate, but exten-
sive screening failed in delivering suitable conditions. In most 
RiPP systems the core peptide sequence is at least to some degree 
variable, but in all bottromycin biosynthetic gene clusters identi-
fied to date the core peptide sequence is fully conserved25-27 (with 
the exception of a single-amino acid change found in one clus-
ter28). This is at odds with the substrate promiscuity observed for 
bottromycin biosynthetic enzymes in vitro thus far8-9, 14. To probe 
the promiscuity of PurAH and the fidelity for macrocyclized in-
termediate, we generated a series of mutant precursor peptides 
(Figure 2c). The degree of conversion was estimated by moni-
toring the consumption of substrate (see SOI for details). Data 
for the mutations are provided in Figures S7 – S20. BotA mutants 
Pro2Ala, Val4Leu, Phe6Trp, and Asp7Asn were found to be 
good substrates of PurAH (Figure 2c). The mutants Val3Leu, 
Val5Ala, and Asp7Ala were fair and Val4Ala, Val5Glu, and 
Phe6Ala were poor substrates of PurAH. Asp7Val could not be 
processed, which may implicate Asp7 in metal coordination. 
While presence of a heterocycle within the S1 site (Using stand-
ard protease nomenclature) of PurAH was essential for activity, 
the S1’ site is more flexible, as demonstrated by partial conver-
sion of BotA mutants Met9Ala and Met9Phe. In all cases where 
turnover was observed, only the mass for heterocyclized, macro-
cyclized product could be detected. These data demonstrate that 
PurAH is promiscuous in the context of single amino-acid 
changes, while retaining a high fidelity for macrocyclized sub-
strate. 
Scheme 2. (a) Proposed mechanism of follower peptide re-
moval by PurAH. It is unclear which residue stabilizes the 
oxyanion. Zn2+-coordinating residues His94 and His229 
have been omitted for clarity (b) Proposed role of PurAH 
in bottromycin biosynthesis. Removal of the follower pep-
tide (green) by PurAH prevents reopening of the 
macroamidine (cyan) and thus drives biosynthesis. 
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It has been demonstrated for amidohydrolases distantly related 
to PurAH that the aspartate residue involved in metal coordina-
tion at the active site (Asp348 in PurAH) and a tyrosine residue 
in proximity of the active site were involved in catalysis (e.g.29). 
In PurAH, the mutation Asp348Asn resulted in a loss of catalytic 
activity (Figure S21). These data may implicate Asp348 as the 
base in catalysis, but we cannot exclude disruption of metal bind-
ing. The only tyrosine residue in the immediate vicinity of the ac-
tive-site Zn2+-ions was Tyr185, and in PurAH the mutant 
Tyr185Phe showed impaired substrate processing (Figure S21).  
We have demonstrated that removal of the follower peptide in 
bottromycin biosynthesis is catalyzed by PurAH. Since the pre-
ceding macroamidine formation is reversible, this enzyme has a 
profound effect on bottromycin biosynthesis by cooperating 
with the YcaO enzyme PurCD to ensure efficient macrocycliza-
tion. This resolves the apparent disparity between in vitro8-9 and 
in vivo13 data and places PurAH as the gatekeeper between pri-
mary and secondary modification steps (Scheme 2). It also adds 
to our understanding of the YcaO superfamily: Thioamide-form-
ing YcaO enzymes appear to require a TfuA protein for activity30, 
while YcaO enzymes installing heterocycles in linear azolic pep-
tides require an E1-like protein31-32 and their activity appears in 
some cases coupled to an FMN-dependent oxidase33-34. Despite 
the cooperation between PurCD and PurAH, we were unable to 
detect complex formation in vitro using various methods (data 
not shown). This raises questions regarding the potential colo-
calization of RiPP enzymes within the producing organism, 
which have only been addressed in a very limited number of RiPP 
systems and require intensive further study. The selectivity of Pu-
rAH for macrocyclized precursor peptides coupled with its sub-
strate promiscuity will be important in future efforts to derivatize 
bottromycins. 
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